ZEB1 promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1

Clinical Cancer Research

Volumn 19, Issue 5, 2013, Pages 1071-1082

  Sánchez Tilló, Ester ^a   De Barrios, Oriol ^a   Siles, Laura ^a   Amendola, Pier G ^a   Darling, Douglas S ^d   Cuatrecasas, Miriam ^b   Castells, Antoni ^a,b   Postigo, Antonio ^a,c,e  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR ZEB1; UROKINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOMA CELL; CELL DEDIFFERENTIATION; CELL INVASION; CELL MIGRATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA STABILITY; STROMA; TRANSCRIPTION INITIATION; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL NEOPLASMS; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; P300-CBP TRANSCRIPTION FACTORS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA STABILITY; RNA, MESSENGER; TRANSCRIPTION, GENETIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WNT PROTEINS;

EID: 84874927009     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2675     Document Type: Article

References (44)

1. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, b-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009;28: 151-66.
2. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop: a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670-7.
3. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012;69: 3429-56.
4. Sanchez-Tillo E, Siles L, de Barrios O, Cuatrecasas M, Vaquero E, Castells A, et al. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res 2011;1: 897-912.
5. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 2011;300: 66-78.
6. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008;68: 537-44.
7. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11: 1487-95.
8. Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 2013;132: 745-54.
9. Shirakihara T, Saitoh M, Miyazono K. Differential regulation of epithelial and mesenchymal markers by dEF1 proteins in epithelial mesenchymal transition induced by TGF-b. Mol Biol Cell 2007;18: 3533-44.
10. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the Notch signaling pathway. Cancer Res 2009;69: 2400-7.
11. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. b-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 2011;108: 19204-9.
12. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, et al.A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006;131: 830-40.
13. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable b-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001;98: 10356-61.
14. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010;29: 3490-500.
15. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol 2011;21: 228-37.
16. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93: 676-81.
17. Papadopoulou S, Scorilas A, Yotis J, Arnogianaki N, Plataniotis G, Agnanti N, et al. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumor Biol 2002;23: 170-8.
18. Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Danø K, et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009;124: 1860-70.
19. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000;60: 5839-47.
20. Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN, et al. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin Cancer Res 2001;7: 2519-26.
21. Durand MK, Bødker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004;91: 438-49.
22. Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4: 923-8.
23. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995;96: 2593-600.
24. Hiendlmeyer E, Regus S, Wassermann S, Hlubek F, Haynl A, Dimmler A, et al. b-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res 2004;64: 1209-14.
25. Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C, Reedijk M. Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res 2011;71: 277-86.
26. Nagamine Y. Transcriptional regulation of the plasminogen activator inhibitor type 1 with an emphasis on negative regulation. Thromb Haemost 2008;100: 1007-13.
27. Takagi T, Moribe H, Kondoh H, Higashi Y. dEF1, a zinc finger and homeodomain transcription factor, is required for skeleton patterning in multiple lineages. Development 1998;125: 21-31.
28. Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M. Nuclear export of the APC tumour suppressor controls b-catenin function in transcription. EMBO J 2003;22: 1101-13.
29. Sekido R, Murai K, Funahashi J, Kamachi Y, Fujisawa-Sehara A, Nabeshima Y, et al. The d-crystallin enhancer-binding protein dEF1 is a repressor of E2-box-mediated gene activation. Mol Cell Biol 1994;14: 5692-700.
30. Postigo A, Depp JL, Taylor JJ, Kroll KL. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J 2003;22: 2453-62.
31. Postigo A. Opposing functions of ZEB proteins in the regulation of the TGFb/BMP signaling pathway. EMBO J 2003;22: 2443-52.
32. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10: 39-49.
33. Matthews H, Ranson M, Kelso MJ. Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty? Int J Cancer 2011;129: 2051-61.
34. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. Urokinase plasminogen activation receptor induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007;178: 425-36.
35. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem 2009;284: 22825-33.
36. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S, et al. Nuclear translocation of urokinase-type plasminogen activator. Blood 2008;112: 100-11.
37. Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 2011;9: 377-89.
38. Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ, et al. Id2 is a target of the b-catenin/T cell factor pathway in colon carcinoma. J Biol Chem 2001;276: 45113-9.
39. Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, Botkjaer KA, Andreasen PA, et al. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. Neoplasia 2011;13: 806-21.
40. Nam EH, Lee Y, Park YK, Lee JW, Kim S. ZEB2 upregulates integrin a5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis 2012;33: 563-71.
41. Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP, Shetty RS. Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem 2008;283: 19570-80.
42. Shetty S, Velusamy T, Shetty RS, Marudamuthu AS, Shetty SK, Florova G, et al. Post-transcriptional regulation of plasminogen activator inhibitor type-1 expression in human pleural mesothelial cells. Am J Respir Cell Mol Biol 2010;43: 358-67.
43. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11: 23-36.
44. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147: 992-1009.